Quick Answer
enGene Therapeutics Inc. reported Total Assets of $221.47 million for the year ending 2025.
- enGene Therapeutics Inc. showed a decrease of -28.8% in Total Assets from 2024 to 2025.
- This data is from enGene Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on December 22, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $93.42 million | Q2 2024: $273.53 million | Q3 2024: $266.88 million | Q1 2025: $285.93 million | Q2 2025: $266.65 million | Q3 2025: $245.55 million | Q4 2025: $221.47 million | Q1 2026: $337.11 million.
- Over the full 4 years of available data (2022 to 2025), enGene Therapeutics Inc.'s Total Assets has grown by 826.3%.
- Historical annual values: Fiscal year 2025: $221.47 million | Fiscal year 2024: $311.17 million | Fiscal year 2023: $86.96 million | Fiscal year 2022: $23.91 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: